Membrane-anchored chemokine fusion proteins

Abstract

Adoptive or active cancer immunotherapy can fail owing to the inefficient recruitment of effector leukocytes to malignant lesions. The intratumoral injection of recombinant proteins comprising a chemokine-derived domain linked to the mucin stalk of chemokine (C-X3-C motif) ligand 1 (CX3CL1) and a glycosylphosphatidylinositol anchor can specifically enhance the recruitment of effector cell subsets to solid tumors.

Keywords: :

• active immunotherapy
• adoptive immunotherapy
• cancer therapy
• chemokine
• endothelial anergy
• GPI anchor
• leukocyte recruitment

Citation: Nelson PJ, Muenchmeier N. Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy. OncoImmunology 2013; 2:e26619; 10.4161/onci.26619

Disclosure of Potential Conflicts of Interest

PJN has patented the technology described here.

Acknowledgments

This work was funded by the Deutsche Forschungsgemeinschaft DFG TR-SFB 36.